F2R and cancer: We previously developed a monoclonal anti-PAR1 antibody and successfully visualized the movements of PAR1-expressing cancer cells during metastasis in vivo by tracking cancer cells labeled with anti-PAR1-QDs, which possess 705-nm peak emission wavelength24.